bibliographic resource 2494573 [br/2494573]
https://w3id.org/oc/corpus/br/2494573

is a
title
  • A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
publication date
  • 2015-01-01
contributor
format
identifier
part of